Terbutaline Injection

Generic name: Pronounced as (ter byoo' ta leen)
Brand names
  • Brethine®
  • Bricanyl®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 07/15/2018

Terbutaline injection is sometimes used to stop or prevent premature labor in pregnant women, however, it is not approved by the Food and Drug Administration for this purpose. Terbutaline injection should only be given to women who are in a hospital and should not be used to treat premature labor for longer than 48 to 72 hours. Terbutaline has caused serious side effects, including death, in pregnant women who took the medication for this purpose. Terbutaline has also caused serious side effects in newborns whose mothers took the medication to stop or prevent labor.

Terbutaline injection is used to treat wheezing, shortness of breath, coughing, and chest tightness caused by asthma, chronic bronchitis, and emphysema. Terbutaline is in a class of medications called beta agonists. It works by relaxing and opening the airways, making it easier to breathe.

Terbutaline injection comes as a solution (liquid) to inject under the skin. It is usually given by a doctor or nurse in a medical facility when needed to treat symptoms of asthma, chronic bronchitis, or emphysema. If the symptoms do not improve within 15 to 30 minutes after the first dose, another dose may be given. If the symptoms do not improve within 15 to 30 minutes after the second dose, a different treatment should be used.

Terbutaline injection is also sometimes used for a short period of time (less than 48 to 72 hours) to treat premature labor in pregnant women who are in a hospital. Talk to your doctor about the risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving terbutaline injection,

  • tell your doctor and pharmacist if you are allergic to terbutaline, any other medications, or any of the ingredients in terbutaline injection. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: beta blockers such as atenolol (Tenormin), carteolol (Cartrol), labetalol (Normodyne, Trandate), metoprolol (Lopressor), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), and timolol (Blocadren); certain diuretics ('water pills'); other medications for asthma; and medications for colds, appetite control, and attention-deficit hyperactivity disorder. Also tell your doctor if you are taking any of the following medications or if you have stopped taking them in the past 2 weeks: tricyclic antidepressants including amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin, imipramine (Tofranil), maprotiline, nortriptyline (Pamelor), protriptyline (Vivactil), and trimipramine (Surmontil) and monoamine oxidase inhibitors (MAOIs) including isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had an irregular heartbeat, heart disease, high blood pressure, an overactive thyroid gland, diabetes, or seizures.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while using terbutaline injection, call your doctor.

Unless your doctor tells you otherwise, continue your normal diet.

  • Terbutaline injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • uncontrollable shaking of a part of the body

    • nervousness

    • dizziness

    • drowsiness

    • weakness

    • headache

    • nausea

    • vomiting

    • sweating

    • flushing (feeling of warmth)

    • pain at the injection site

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:

    • increased difficulty breathing

    • tightening of the throat

    • fast, pounding, or irregular heartbeat

    • chest pain

    • seizures

  • Terbutaline injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • chest pain

  • fast, pounding, or irregular heartbeat

  • dizziness or fainting

  • nervousness

  • headache

  • uncontrollable shaking of a part of the body

  • excessive tiredness

  • difficulty falling asleep or staying asleep

  • weakness

  • dry mouth

  • seizures

Keep all appointments with your doctor.

Ask your pharmacist any questions you have about terbutaline injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Moxifloxacin.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dolasetron.
Aminophylline Aminophylline The risk or severity of adverse effects can be increased when Terbutaline is combined with Aminophylline.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Anagrelide.
Candesartan Candesartan Terbutaline may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cilostazol.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Fenofibrate Fenofibrate Terbutaline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Guanfacine Guanfacine Terbutaline may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Magnesium Hydroxide Magnesium Hydroxide Terbutaline may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Methylergonovine Methylergonovine Methylergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline.
Mycophenolate Mycophenolate Terbutaline may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of hypertension can be increased when Terbutaline is combined with Naratriptan.
Olsalazine Olsalazine Olsalazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Penbutolol Penbutolol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Acebutolol.
Potassium Potassium Potassium may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prednisone.
Ranitidine Ranitidine Ranitidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Reserpine Reserpine Reserpine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Rizatriptan Rizatriptan Terbutaline may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Sumatriptan Sumatriptan Sumatriptan may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tacrolimus Tacrolimus Tacrolimus may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Terbutaline.
Triamcinolone Triamcinolone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Terbutaline.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Famotidine.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Terbutaline.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection Hydromorphone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levofloxacin.
Meperidine Injection Meperidine Injection Meperidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Methylprednisolone Injection Methylprednisolone Injection The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metronidazole.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Terbutaline may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine Amphetamine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cyclosporine Cyclosporine Cyclosporine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ondansetron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Granisetron.
Torsemide Torsemide The risk or severity of hypokalemia can be increased when Torasemide is combined with Terbutaline.
Olanzapine Olanzapine The therapeutic efficacy of Olanzapine can be decreased when used in combination with Terbutaline.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dofetilide.
Eprosartan Eprosartan Terbutaline may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Hydroxychloroquine.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Pantoprazole Pantoprazole Pantoprazole may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Telmisartan Telmisartan Terbutaline may decrease the antihypertensive activities of Telmisartan.
Temozolomide Temozolomide Temozolomide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Zaleplon Zaleplon Terbutaline may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Desloratadine.
Linezolid Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Terbutaline.
Trimipramine Trimipramine The risk or severity of hypertension can be increased when Trimipramine is combined with Terbutaline.
Glycopyrrolate Glycopyrrolate The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Terbutaline.
Perindopril Perindopril Perindopril may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Dutasteride Dutasteride The risk or severity of hypertension can be increased when Terbutaline is combined with Dutasteride.
Epinephrine Injection Epinephrine Injection The therapeutic efficacy of Terbutaline can be increased when used in combination with Epinephrine.
Eplerenone Eplerenone Eplerenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Escitalopram.
Olmesartan Olmesartan Terbutaline may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide Terbutaline may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Aripiprazole Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Terbutaline.
Atomoxetine Atomoxetine Atomoxetine may increase the tachycardic activities of Terbutaline.
Dexmethylphenidate Dexmethylphenidate The risk or severity of hypertension can be increased when Terbutaline is combined with Dexmethylphenidate.
Teriparatide Injection Teriparatide Injection The risk or severity of adverse effects can be increased when Terbutaline is combined with Teriparatide.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Almotriptan Almotriptan Terbutaline may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Eletriptan Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with Terbutaline.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Terbutaline.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Terbutaline.
Alfuzosin Alfuzosin The therapeutic efficacy of Terbutaline can be decreased when used in combination with Alfuzosin.
Emtricitabine Emtricitabine Terbutaline may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Memantine Memantine Terbutaline may decrease the excretion rate of Memantine which could result in a higher serum level.
Tadalafil Tadalafil Tadalafil may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Frovatriptan Frovatriptan The risk or severity of hypertension can be increased when Terbutaline is combined with Frovatriptan.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gemifloxacin.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Terbutaline.
Protriptyline Protriptyline The risk or severity of hypertension can be increased when Protriptyline is combined with Terbutaline.
Duloxetine Duloxetine Duloxetine may increase the tachycardic activities of Terbutaline.
Tinidazole Tinidazole Terbutaline may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Trospium Trospium The therapeutic efficacy of Trospium can be decreased when used in combination with Terbutaline.
Bosentan Bosentan Terbutaline may decrease the antihypertensive activities of Bosentan.
Cefditoren Cefditoren Cefdinir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erlotinib.
Eszopiclone Eszopiclone Eszopiclone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ganciclovir Ganciclovir Terbutaline may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Ribavirin Ribavirin Ribavirin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Solifenacin.
Valganciclovir Valganciclovir Terbutaline may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Terbutaline.
Adefovir Adefovir Adefovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine Amphetamine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terbutaline.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.
Ramelteon Ramelteon Terbutaline may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Darifenacin Darifenacin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Terbutaline.
Fentanyl Fentanyl The risk or severity of hypertension can be increased when Fentanyl is combined with Terbutaline.
Pregabalin Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Terbutaline.
Phenylephrine Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Terbutaline.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Felbamate.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ranolazine.
Rasagiline Rasagiline Terbutaline may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Imatinib.
Sitagliptin Sitagliptin Terbutaline may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Varenicline Varenicline Terbutaline may decrease the excretion rate of Varenicline which could result in a higher serum level.
Albuterol Albuterol The risk or severity of adverse effects can be increased when Terbutaline is combined with Salbutamol.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Terbutaline.
Clofarabine Injection Clofarabine Injection Clofarabine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Lubiprostone Lubiprostone Terbutaline may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Posaconazole.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Primaquine.
Aliskiren Aliskiren Terbutaline may decrease the antihypertensive activities of Aliskiren.
Pemetrexed Injection Pemetrexed Injection Terbutaline may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The risk or severity of adverse effects can be increased when Terbutaline is combined with Lisdexamfetamine.
Nabilone Nabilone The risk or severity of Tachycardia can be increased when Nabilone is combined with Terbutaline.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Terbutaline.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sunitinib.
Dronabinol Dronabinol The risk or severity of Tachycardia can be increased when Dronabinol is combined with Terbutaline.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levocetirizine.
Pegaptanib Injection Pegaptanib Injection Terbutaline may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dasatinib.
Azacitidine Injection Azacitidine Injection Terbutaline may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Lenalidomide Lenalidomide Lenalidomide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Toremifene.
Budesonide Budesonide The therapeutic efficacy of Terbutaline can be decreased when used in combination with Budesonide.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Doripenem Injection Doripenem Injection Terbutaline may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine Desvenlafaxine may increase the tachycardic activities of Terbutaline.
Cevimeline Cevimeline Cevimeline may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nebivolol Nebivolol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Nebivolol.
Pilocarpine Pilocarpine The risk or severity of adverse effects can be increased when Terbutaline is combined with Pilocarpine.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Flecainide.
Certolizumab Injection Certolizumab Injection Terbutaline may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Irinotecan Injection Irinotecan Injection Terbutaline may increase the neuromuscular blocking activities of Irinotecan.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Methylnaltrexone Injection Methylnaltrexone Injection Terbutaline may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Silodosin Silodosin The therapeutic efficacy of Terbutaline can be decreased when used in combination with Silodosin.
Midazolam Midazolam Midazolam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Milnacipran Milnacipran Milnacipran may increase the tachycardic activities of Terbutaline.
Plerixafor Injection Plerixafor Injection Terbutaline may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine Fesoterodine The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Terbutaline.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Degarelix.
Betaxolol Betaxolol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Iloperidone.
Prasugrel Prasugrel Terbutaline may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone Dronedarone The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dronedarone.
Pralatrexate Injection Pralatrexate Injection Terbutaline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection Palonosetron may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Saxagliptin Saxagliptin Terbutaline may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Romidepsin.
Topotecan Topotecan Terbutaline may decrease the excretion rate of Topotecan which could result in a higher serum level.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Asenapine.
Dalfampridine Dalfampridine Terbutaline may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Eribulin.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection Acetaminophen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Vilazodone Vilazodone The risk or severity of hypertension can be increased when Terbutaline is combined with Vilazodone.
Ipilimumab Injection Ipilimumab Injection Terbutaline may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Roflumilast Roflumilast Terbutaline may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Rilpivirine.
Potassium Iodide Potassium Iodide The risk or severity of adverse effects can be increased when Terbutaline is combined with Potassium Iodide.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Triptorelin.
Rivaroxaban Rivaroxaban Terbutaline may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib Ruxolitinib Terbutaline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Vandetanib.
Clobazam Clobazam Clobazam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Vemurafenib.
Deferiprone Deferiprone Terbutaline may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Crizotinib.
Cabergoline Cabergoline Cabergoline may increase the hypertensive and vasoconstricting activities of Terbutaline.
Naloxone Injection Naloxone Injection Terbutaline may decrease the excretion rate of Naloxone which could result in a higher serum level.
Ambrisentan Ambrisentan Terbutaline may decrease the antihypertensive activities of Ambrisentan.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Enzalutamide Enzalutamide Terbutaline may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mirabegron.
Corticotropin, Repository Injection Corticotropin, Repository Injection The therapeutic efficacy of Terbutaline can be decreased when used in combination with Corticotropin.
Teduglutide Injection Teduglutide Injection Terbutaline may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Bedaquiline.
Alogliptin Alogliptin Terbutaline may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Pomalidomide Pomalidomide Terbutaline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Canagliflozin Canagliflozin Terbutaline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dabrafenib.
Trametinib Trametinib Terbutaline may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran Levomilnacipran Levomilnacipran may increase the tachycardic activities of Terbutaline.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Vortioxetine Vortioxetine Terbutaline may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Sofosbuvir Sofosbuvir Terbutaline may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin Dapagliflozin Dapagliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Apremilast Apremilast Terbutaline may decrease the excretion rate of Apremilast which could result in a higher serum level.
Droxidopa Droxidopa The therapeutic efficacy of Terbutaline can be increased when used in combination with Droxidopa.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ceritinib.
Testosterone Injection Testosterone Injection Testosterone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Edoxaban Edoxaban Terbutaline may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Methamphetamine Methamphetamine Terbutaline may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tasimelteon Tasimelteon Terbutaline may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Riociguat Riociguat Terbutaline may decrease the antihypertensive activities of Riociguat.
Risperidone Injection Risperidone Injection The therapeutic efficacy of Terbutaline can be decreased when used in combination with Risperidone.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan Macitentan Terbutaline may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin The risk or severity of hypertension can be increased when Terbutaline is combined with Flibanserin.
Prednisolone Prednisolone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prednisolone.
Brexpiprazole Brexpiprazole The therapeutic efficacy of Terbutaline can be decreased when used in combination with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ziprasidone.
Cariprazine Cariprazine The risk or severity of hypertension can be increased when Terbutaline is combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Terbutaline may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Ixazomib Ixazomib Terbutaline may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Terbutaline may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Dexamethasone Injection Dexamethasone Injection The therapeutic efficacy of Terbutaline can be decreased when used in combination with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection Terbutaline may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Midodrine Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Terbutaline.
Selexipag Selexipag Terbutaline may decrease the antihypertensive activities of Selexipag.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection The risk or severity of hypokalemia can be increased when Furosemide is combined with Terbutaline.
Lixisenatide Injection Lixisenatide Injection Terbutaline may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ribociclib.
Parathyroid Hormone Injection Parathyroid Hormone Injection The risk or severity of adverse effects can be increased when Terbutaline is combined with Parathyroid hormone.
Doxepin (Insomnia) Doxepin (Insomnia) The therapeutic efficacy of Doxepin can be decreased when used in combination with Terbutaline.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Deutetrabenazine.
Valbenazine Valbenazine Terbutaline may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Deflazacort Deflazacort The therapeutic efficacy of Terbutaline can be decreased when used in combination with Deflazacort.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Safinamide is combined with Terbutaline.
Naldemedine Naldemedine Terbutaline may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Abaloparatide Injection Abaloparatide Injection The risk or severity of adverse effects can be increased when Terbutaline is combined with Abaloparatide.
Benznidazole Benznidazole Terbutaline may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Delafloxacin.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin Ertugliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Apalutamide Apalutamide Terbutaline may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Baricitinib Baricitinib Terbutaline may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lofexidine.
Plazomicin Injection Plazomicin Injection Terbutaline may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ivosidenib.
Cannabidiol Cannabidiol The risk or severity of Tachycardia can be increased when Cannabidiol is combined with Terbutaline.
Stiripentol Stiripentol Terbutaline may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Glasdegib.
Prucalopride Prucalopride Terbutaline may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Siponimod Siponimod The risk or severity of hypertension can be increased when Terbutaline is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Terbutaline.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Entrectinib.
Pitolisant Pitolisant Terbutaline may increase the QTc-prolonging activities of Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Terbutaline.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Terbutaline is combined with Selpercatinib.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fostemsavir.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terbutaline.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Terbutaline is combined with Naxitamab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Relugolix.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine Viloxazine Terbutaline may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Theophylline Theophylline The risk or severity of adverse effects can be increased when Terbutaline is combined with Theophylline.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Terbutaline.
Isotretinoin Isotretinoin Terbutaline may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Phenobarbital Phenobarbital The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Terbutaline.
Metaxalone Metaxalone Metaxalone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Primidone Primidone The therapeutic efficacy of Primidone can be decreased when used in combination with Terbutaline.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Methsuximide.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Terbutaline is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Terbutaline.
Diazepam Diazepam Diazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Oxazepam Oxazepam Oxazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Flurazepam Flurazepam Flurazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Clorazepate Clorazepate Clorazepic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Lorazepam Lorazepam Lorazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Phenoxybenzamine Phenoxybenzamine The therapeutic efficacy of Terbutaline can be decreased when used in combination with Phenoxybenzamine.
Carmustine Carmustine Carmustine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Amantadine.
Codeine Codeine Codeine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Bromocriptine Bromocriptine Bromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline.
Metaproterenol Metaproterenol The risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline.
Tranylcypromine Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.
Phenelzine Phenelzine Phenelzine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Terbutaline.
Ergoloid Mesylates Ergoloid Mesylates Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Terbutaline.
Tetracycline Tetracycline Tetracycline may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Thioridazine.
Trifluoperazine Trifluoperazine The therapeutic efficacy of Terbutaline can be decreased when used in combination with Trifluoperazine.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Sulfadiazine Sulfadiazine Sulfadiazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Methadone Methadone The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Methadone.
Oxybutynin Oxybutynin The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Terbutaline.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Maprotiline.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Terbutaline.
Orphenadrine Orphenadrine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Orphenadrine.
Azathioprine Azathioprine Terbutaline may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Phentermine Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline.
Methylphenidate Methylphenidate Methylphenidate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Amoxapine Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Terbutaline.
Sulfasalazine Sulfasalazine Sulfasalazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Hydrocortisone Hydrocortisone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Hydrocortisone.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Carbamazepine Carbamazepine Terbutaline may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Methyldopa Methyldopa Terbutaline may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine Clonidine The risk or severity of hypertension can be increased when Clonidine is combined with Terbutaline.
Prazosin Prazosin The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prazosin.
Hydralazine Hydralazine Terbutaline may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine Cimetidine Cimetidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Warfarin Warfarin Terbutaline may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam Clonazepam Terbutaline may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Loperamide.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Promethazine.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Digoxin Digoxin Terbutaline may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine Loxapine The therapeutic efficacy of Terbutaline can be decreased when used in combination with Loxapine.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chloroquine.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Terbutaline.
Triamterene Triamterene Triamterene may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Chlorothiazide Chlorothiazide Terbutaline may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Terbutaline may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Metolazone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital Secobarbital The therapeutic efficacy of Secobarbital can be decreased when used in combination with Terbutaline.
Desipramine Desipramine The risk or severity of hypertension can be increased when Terbutaline is combined with Desipramine.
Amitriptyline Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Terbutaline.
Imipramine Imipramine The therapeutic efficacy of Imipramine can be decreased when used in combination with Terbutaline.
Probenecid Probenecid Terbutaline may decrease the excretion rate of Probenecid which could result in a higher serum level.
Quinidine Quinidine Terbutaline may decrease the excretion rate of Quinidine which could result in a higher serum level.
Procainamide Procainamide Terbutaline may decrease the excretion rate of Procainamide which could result in a higher serum level.
Isoniazid Isoniazid Terbutaline may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Terbutaline.
Butabarbital Butabarbital The therapeutic efficacy of Butabarbital can be decreased when used in combination with Terbutaline.
Levothyroxine Levothyroxine The risk or severity of adverse effects can be increased when Terbutaline is combined with Levothyroxine.
Liothyronine Liothyronine The risk or severity of adverse effects can be increased when Liothyronine is combined with Terbutaline.
Methimazole Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Terbutaline.
Propylthiouracil Propylthiouracil The risk or severity of adverse effects can be increased when Terbutaline is combined with Propylthiouracil.
Chlorpropamide Chlorpropamide Chlorpropamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tolbutamide Tolbutamide Terbutaline may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolazamide Tolazamide Tolazamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Dextromethorphan Dextromethorphan The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Terbutaline.
Baclofen Baclofen Baclofen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Doxylamine Doxylamine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Doxylamine.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terbutaline.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Methyclothiazide Methyclothiazide Terbutaline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Chlorzoxazone Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Terbutaline.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) Propranolol may decrease the bronchodilatory activities of Terbutaline.
Minoxidil Minoxidil Terbutaline may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Terbutaline.
Nortriptyline Nortriptyline The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Terbutaline.
Spironolactone Spironolactone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Spironolactone.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Mercaptopurine Mercaptopurine The risk or severity of adverse effects can be increased when Terbutaline is combined with Mercaptopurine.
Phytonadione Phytonadione Terbutaline may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nadolol Nadolol Nadolol may decrease the bronchodilatory activities of Terbutaline.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terbutaline.
Flavoxate Flavoxate The therapeutic efficacy of Flavoxate can be decreased when used in combination with Terbutaline.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluorouracil.
Colchicine Colchicine Terbutaline may decrease the excretion rate of Colchicine which could result in a higher serum level.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Dacarbazine Dacarbazine Dacarbazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Acetazolamide Acetazolamide Acetazolamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Terbutaline.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ketoconazole.
Pyrantel Pyrantel Terbutaline may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Captopril Captopril Terbutaline may decrease the antihypertensive activities of Captopril.
Dipyridamole Dipyridamole The therapeutic efficacy of Terbutaline can be decreased when used in combination with Dipyridamole.
Isoxsuprine Isoxsuprine The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoxsuprine.
Bethanechol Bethanechol The risk or severity of adverse effects can be increased when Terbutaline is combined with Bethanechol.
Ethacrynic Acid Ethacrynic Acid The risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Terbutaline.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Metoprolol Metoprolol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Terbutaline.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Thiothixene.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Alprazolam Alprazolam Alprazolam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Temazepam Temazepam Temazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Triazolam Triazolam Terbutaline may decrease the excretion rate of Triazolam which could result in a higher serum level.
Dicyclomine Dicyclomine The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Terbutaline.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Hyoscyamine.
Propantheline Propantheline The therapeutic efficacy of Propantheline can be decreased when used in combination with Terbutaline.
Trimethoprim Trimethoprim Trimethoprim may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Diltiazem.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nifedipine.
Timolol Timolol Timolol may decrease the bronchodilatory activities of Terbutaline.
Verapamil Verapamil The therapeutic efficacy of Terbutaline can be decreased when used in combination with Verapamil.
Atenolol Atenolol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Atenolol.
Pindolol Pindolol Pindolol may decrease the bronchodilatory activities of Terbutaline.
Cisplatin Injection Cisplatin Injection Terbutaline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal Diflunisal may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Bumetanide Bumetanide The risk or severity of hypokalemia can be increased when Terbutaline is combined with Bumetanide.
Glyburide Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Terbutaline.
Glipizide Glipizide Terbutaline may decrease the excretion rate of Glipizide which could result in a higher serum level.
Indapamide Indapamide Indapamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin Amoxicillin Terbutaline may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Oxacillin Injection Oxacillin Injection Oxacillin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Pentoxifylline Pentoxifylline The risk or severity of adverse effects can be increased when Terbutaline is combined with Pentoxifylline.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pentamidine.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Labetalol Labetalol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Labetalol.
Auranofin Auranofin Terbutaline may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Leuprolide.
Gemfibrozil Gemfibrozil Terbutaline may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Guanabenz Guanabenz The risk or severity of hypertension can be increased when Guanabenz is combined with Terbutaline.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pimozide.
Enalapril Enalapril Terbutaline may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Buspirone Buspirone Buspirone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ciprofloxacin.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Fluoxetine Fluoxetine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nimodipine.
Clozapine Clozapine The therapeutic efficacy of Clozapine can be decreased when used in combination with Terbutaline.
Estazolam Estazolam Terbutaline may decrease the excretion rate of Estazolam which could result in a higher serum level.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ofloxacin.
Didanosine Didanosine Terbutaline may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Clarithromycin.
Benazepril Benazepril Terbutaline may decrease the antihypertensive activities of Benazepril.
Etodolac Etodolac Etodolac may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Terbutaline.
Fosinopril Fosinopril Fosinopril may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Quinapril Quinapril Terbutaline may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Terbutaline may decrease the antihypertensive activities of Ramipril.
Amlodipine Amlodipine Terbutaline may decrease the antihypertensive activities of Amlodipine.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Itraconazole.
Lisinopril Lisinopril Lisinopril may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Sotalol Sotalol Sotalol may decrease the bronchodilatory activities of Terbutaline.
Bisoprolol Bisoprolol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Bisoprolol.
Doxazosin Doxazosin The therapeutic efficacy of Terbutaline can be decreased when used in combination with Doxazosin.
Terazosin Terazosin The therapeutic efficacy of Terbutaline can be decreased when used in combination with Terazosin.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Terbutaline.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cisapride.
Venlafaxine Venlafaxine Venlafaxine may increase the tachycardic activities of Terbutaline.
Fluvoxamine Fluvoxamine Fluvoxamine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nefazodone Nefazodone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lamotrigine.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Terbutaline.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tramadol Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Terbutaline.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Terbutaline.
Ifosfamide Injection Ifosfamide Injection Terbutaline may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Nicardipine Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Terbutaline.
Bupropion Bupropion Terbutaline may decrease the excretion rate of Bupropion which could result in a higher serum level.
Ticlopidine Ticlopidine Ticlopidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Saquinavir.
Metformin Metformin Metformin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nisoldipine Nisoldipine Nisoldipine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Lamivudine Lamivudine Lamivudine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Acarbose Acarbose Acarbose may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Gemcitabine Injection Gemcitabine Injection Gemcitabine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Ritonavir Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Terbutaline.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Clomipramine Clomipramine The risk or severity of hypertension can be increased when Terbutaline is combined with Clomipramine.
Fosfomycin Fosfomycin Fosfomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Mirtazapine Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Terbutaline.
Trandolapril Trandolapril Terbutaline may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate Topiramate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Valsartan Valsartan Terbutaline may decrease the antihypertensive activities of Valsartan.
Pramipexole Pramipexole Pramipexole may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Terbutaline.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Azithromycin.
Carvedilol Carvedilol The therapeutic efficacy of Terbutaline can be decreased when used in combination with Carvedilol.
Nilutamide Nilutamide Nilutamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Flutamide Flutamide Flutamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline.
Propafenone Propafenone The therapeutic efficacy of Terbutaline can be decreased when used in combination with Propafenone.
Irbesartan Irbesartan Terbutaline may decrease the antihypertensive activities of Irbesartan.
Tamsulosin Tamsulosin The therapeutic efficacy of Terbutaline can be decreased when used in combination with Tamsulosin.
Finasteride Finasteride The risk or severity of hypertension can be increased when Terbutaline is combined with Finasteride.
Quetiapine Quetiapine The therapeutic efficacy of Quetiapine can be decreased when used in combination with Terbutaline.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Terbutaline.
Paroxetine Paroxetine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Terbutaline.
Tolcapone Tolcapone Tolcapone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Citalopram.
Capecitabine Capecitabine Terbutaline may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Efavirenz.
Abacavir Abacavir Terbutaline may decrease the excretion rate of Abacavir which could result in a higher serum level.
Celecoxib Celecoxib Celecoxib may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Rosiglitazone Rosiglitazone Rosiglitazone may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Tolterodine.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Balsalazide Balsalazide Balsalazide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Nateglinide Nateglinide Nateglinide may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Terbutaline.
Rabeprazole Rabeprazole Terbutaline may decrease the excretion rate of Rabeprazole which could result in a higher serum level.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists